Classical hematologist; hemostasis/thrombosis, hemophilia, VWD, rare bleeding disorders specialist; severe hemophilia A blood brother🩸, opinions my own
Illinois, USA
Joined December 2019
- Tweets1.1K
- Following745
- Followers784
- Likes1.8K
Pinned Tweet
Happy to share a recent publication to kick off bleeding disorders awareness month!
mdpi.com/2077-0383/15/4/1517…
J Roberts retweeted
In a recent interview, @JonRob08 of @BloodExpertsIL discusses the findings of a study evaluating joint health status & bleeding phenotype in patients with severe & non-severe #hemophilia A or B using musculoskeletal ultrasound and other clinical tools.🩸
Watch here: 👉 ow.ly/YRzs50XLmKr
#Hematology #ASH25
Interesting news and was really only a matter of time. Companies should listen to patients, and each individual weigh risks/benefits of all evolving hemophilia therapies. Sometimes patience is the wise approach. #hemophilia #genetherapy
reuters.com/business/healthc…
Happy to share our study of recombinant VWF real-world treatment patterns and outcomes at 11 centers in the U.S. We demonstrate that routine rVWF prophylaxis reduced bleed rate and healthcare resource utilization compared to prior VWD treatments. #VWD #VWF tandfonline.com/doi/full/10.…
Proud to work with esteemed colleagues to improve future research priorities. The patient voice, through lived experience experts, must be incorporated into cutting-edge research programs from start to finish. ashpublications.org/bloodadv…
J Roberts retweeted
Honored to receive the Mary Draeger Schultz scholarship 2024 @OSFHealthCare!
Grateful for the opportunity to promote #QI and #PatientSafety in healthcare, and for the incredible support from @UICOMPeoria @UicompP
J Roberts retweeted
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and VWD. onlinelibrary.wiley.com/doi/… This article developed by a global team of 48 experts and international organizations rigorously examines a number of GRADE methodology adaptations.
J Roberts retweeted
Come say Hi! 🍷
Poster number: 5014
xitter.cf/docrishabhsingh/status…
Poster 1: Comparing Perioperative Anticoagulation Management Guidelines across U.S. Institutions, working with Venous thromboEmbolism Network U.S #SBH group
📅 Monday, Dec 9, 2024 | 6:00–8:00 PM
📍 Session 901
#AnticoagulationStewardship
@heme_fan @RosovskyRachel @YoukhanaMD
J Roberts retweeted
A critique of the ISTH Haemophilia Guidelines was published in #Haemophilia Journal today with 49 eminent authors representing a global mixture of expertise, all united in their serious concerns about these guidelines which were already outdated on publication 1/3
J Roberts retweeted
Here is our just published review in #Blood focusing on how new biological insights into #FVIII
are setting the stage for new #hemophilia therapies.
#hemesky #medsky
authors.elsevier.com/a/1k8Qn…
J Roberts retweeted
With 70% of bleeding events linked to identified or suspected causes, this study highlights the pressing need for better strategies, including long-term VWD factor (VWF) prophylaxis, to reduce hospitalizations and improve quality of life. Read More: bit.ly/3UWiu6Z
J Roberts retweeted
Centessa have discontinued development of their rebalancing agent, Serpin PC despite encouraging Phase 2 PREScent clinical trial results Decision due to competition from marstacimab and possibly concizumab. This leaves these 2 plus Fitusiran in trials or licenced @ProfMakris
J Roberts retweeted
I strongly disagree with this commentary in the journal Blood Transfusion. The authors try to justify the decision of the @WHO to have cryoprecipitate and pathogen reduced cryoprecipitate (rather than FVIII concentrate) for the treatment of #hemophilia in the list of essential medicines. I do not know of ANY hemophilia treater who agrees with the World Health Organisation policy. What they recommend is dangerous for persons with #hemophilia in poor countries. Pathogen reduced cryo is only available in a tiny number of countries (?2). So essentially they are recommending unsafe cryoprecipitate and suggesting these poor countries introduce the technology to pathogen reduce the cryoprecipitate. It is about time that the @WHO includes hemophilia treaters in the "expert panel" who make recommendations for treatment of persons with hemophilia. tinyurl.com/mtuyt5fs
ATIII deficiency can significantly increase thrombosis risk, particularly VTE. Recurrent thrombosis in 58.6% of patients (44.8%) despite AC. 35% of patients received ATIII concentrate and 84% of these for prophylaxis. jthjournal.org/article/S1538…
ATIII deficiency requires prospective studies to optimize management for these patients @DrDeSancho @BloodExpertsIL @JTHjournal @UICOMPeoria @UICOMPeoriaPeds
J Roberts retweeted
Congratulations Dr @leslieskeith!! Amazing work.
Curious to know if vWD affects pregnancy outcome❓
This multi-center cohort study finds no significant difference in pregnancy loss risk between women with von Willebrand disease (VWD), those with similar bleeding disorders, and non-bleeding controls (OR of pregnancy losses in the VWD group versus non-VWD group was 0.94, 95% CI 0.65, 1.36).
✍️ @leslieskeith @james_paulad @PKouides @lisa_duffett @sholzberg @ragnmv @CukerMd
Read more at jthjournal.org/article/S1538…
